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1. Introduction 
Over the past 35 years, we have observed a remarkable and important increase in the 
prevalence of HPV infection, both in its clinical forms and appearance of its condyloma 
acuminate.  Colposcopic exploration of this area would be required, with special focus at the 
regions of introitus and inter-labial folds. Both genital and anal examinations (Guerra-Tapia 
et al., 2009) are necessary to determine the sub-clinical expression of HPV identified by 
cytological changes, colposcopy, and/or vulvoscopy and vaginoscopy. Clinical forms of 
HPV infections generally caused by LR-HPV strains (6, 11) tend to be benign. Sub-clinical 
forms include benign and pre-malignant lesions, and are generally caused by HR-HPV 
strains (16 and 18) (Fig. 1) (Rodríguez-Cerdeira C et al., 2008a, 2008b, , 2009a; Walboomers et 
al., 1999). In a recent study by the  International Agency for Cancer Research  (IACR) group 
in 13 areas in 11 countries including Spain, a high prevalence of HPV was seen in both 
Europe and Sub-Saharan Africa (International Agency for Research on Cancer [IARC], 1995; 
Muñoz et al., 2003). Furthermore, it was observed that HPV-16 infection was more frequent 
among European women. We observed the same genotype in a study involving 436 women 
aged between 16 and 80 years. Three samples from the cervix and vagina of each patient 
were cytologically examined (Rodríguez-Cerdeira C et al., 2009b).  
Thus, epidemiological studies supported by molecular techniques and liquid cytology have 
confirmed the incidental role of certain strains of HPV in the development of cervical, 
vulvar, vaginal, anal, and penile cancer (Fig. 2), the risk for which is greatly increased in 
human immunodeficiency virus (HIV)+ patients (Rodríguez Cerdeira C et al., 2011). An 
international series with high-sensitivity polymerase chain reaction (PCR) has proven that 
HPV DNA is present in 90.7% of cervical–uterine carcinomas and is present in all the cases 
confirmed by exhaustive histological examination. This also occurs in the majority of 
intraepithelial lesions of the lower genital tract (Walboomers et., 1999).  
Persistent HPV infection is considered the principal causative agent of cervical and other 
anogenital cancers. The finding that HPV DNA is present in practically all cases of cervical 
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cancer has great importance in developing preventive strategies (Fig. 3) (Rodríguez Cerdeira 
C et al., 2007; Mougin et al., 2001; Trottier et al., 2006). Integration of the viral genome with 
the host cell genome does not occur in all cases of cervical cancer and may be explained by 
mutations in repressive areas such as the region Ying-Yang (YYI), which would maintain the 
continued expression of E6 and E7 or by the production of a more stable ‘chimeric’ RNA, 
thereby permitting greater synthesis of these oncoproteins (Fig. 4) (Alba et al., 2009). 
 
Fig. 1. High-grade vulvar intraepithelial neoplasia  in a smoker 
 
Fig. 2. Penile intraepithelial neoplasia developing into invasive carcinoma with extensive 
exophytic ulcerous mass that invades the gland and projects beyond the preputial-balanic 
fold in a human papillomavirus-positive patient 
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Fig. 3. Interaction between the viral protein and the cell cycle 
 
Fig. 4. Integration of human papillomavirus in the host genome  
Over the recent years, the morbimortality and health costs associated with cervical, vaginal, 
vulvar, anal, and peneal cancers and their precursory lesions have provoked intense 
investigation (Kadish et al., 1992; Guerra-Tapia et al., 2009; Rodríguez-Cerdeira C et al., 
2008a) to achieve vaccine-based prevention of HPV infections, which would dramatically 
reduce the risk of these cancers. Experiences with girls or women with current infection 
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with 1 or more of the vaccine HPV types gained protection from the infections or diseases 
caused by the remaining vaccine HPV types, and they were also protected against re-
infection with the same HPV type after clearance of an infection caused by a vaccine HPV 
type. High seroconversion rates and high levels of anti-HPV antibodies were observed in all 
vaccinated individuals of all age ranges from 9 to 45 years. Rechallenge with a quadrivalent 
HPV vaccine produced a potent anamnestic humoral immune response (Rodríguez Cerdeira 
C et al., 2009a, 2009b; Alba et al., 2009). The vaccine is generally well tolerated, and is 
projected to be cost effective in most pharmacoeconomic models. However, there are some 
questions that we are faced with: Does the intensity of such a humoral immune response 
correlate with long-term protection? Although a direct correlation between antibody levels 
and protection may seem intuitively obvious, it is still unclear whether differing antibody 
titres indicate better disease protection or longer duration of immune protection. Given that 
virtually all vaccinated women are seroconverted, we may deduce that until now, we do not 
have any immunological correlates for protection. The question still remains unanswered: 
Why, when the body's natural antibodies respond so poorly, do the HPV vaccines that 
generate serum neutralizing antibodies work? The answer is that the quality and quantity of 
the immune response generated by the vaccine is different from those by natural infections. 
Is it stated that vaccines will induce a generation of long-lived memory immune cells that, 
after re-exposure to the relevant antigen, will generate a potent immune response, thus 
preventing HPV infections? Time is needed to suitably answer this question. In the opinion 
of other investigators, preventive HPV vaccination is an expensive practice, and it may be 
an insufficient tool to tackle cervical cancer worldwide. Therapeutic intervention is seeking 
for safe/effective vaccines inducing the activation of CD8+ cytotoxic T lymphocytes (CTLs) 
that are required to clear the tumour. Linking a tumour-specific antigen (i.e. E7 oncoprotein 
of ‘high-risk’ HPVs) to molecules able to increase its immune ‘visibility’ represents a 
strategy to force the immune system to fight cancer. They focussed on plants as sources of 
innovative immunostimulatory sequences. Thus, a new vaccination route for systemic and 
mucosal immunity, and other issues will be addressed throughout this chapter.  
2. HPV infection and immunity 
Any viral infection requires the presence of a cellular receptor that allows for the 
internalisation of the viral particles. This circumstance supposes the principal barrier to 
entry and explains the species-specific and even organ-specific nature of viral infections. 
Some viruses use the major histocompatibility complexes I and II (MHC I and II) as 
receptors for their internalisation, while others use molecules on the cellular surface (CD4, 
chemokines, growth factors, and ǃ2 microglobulin). The HPV does not have a specific 
cellular receptor but rather has a well-conserved surface molecule with vital cellular 
functions, which makes its use impossible as a target for blocking infection. As opposed to 
other viruses, it does not appear that the surface receptors are implied in tissue or species 
specificity or in HPV tropism (Alba et al., 2009). 
Infection recognition by the host cell and specific tropism of each viral subgroup determine 
the cytopathic effects in specific tissues (Rodríguez-Cerdeira C et al., 2008a ); this makes it 
possible to distinguish between latent infections that do not show their effects for long 
periods and active infections that have practically immediate cytopathic effects. Based on 
these parameters, it is possible to qualify the antigenic or immunogenic level of each virus to 
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comprise the knowledge base for the manufacture of therapeutic or prophylactic vaccines 
(Alba et al., 2009; Rodríguez-Cerdeira et al., 2009c). 
2.1 Cellular and humoral immunity to human papillomavirus  
Cellular immunity is principally represented by T cells, which act at the local tissue level via 
close cell-cell contact. The humoral response is measured by B cells according to the 
instructions from T helper cells, through antibody production. The T cells recognise proteins 
on the surface of the HPV that are associated with the molecules from the cellular surface 
(human leukocyte antigen [HLA]), while the antibodies recognise both surface and soluble 
antigens. In the latter case, this is done with greater specificity. The T-cell receptors 
recognise specific sequences of small peptides presented by the MHC, while the antibodies 
recognise steric three-dimensional structures with determined structures. If correct 
presentation of the antigen is essential for inducing an immunological response, the kinetics 
of antigen-antibody joining and the number and distribution of these joins would be the 
factors determining the immunological response level. 
In general, after the first infection of the cervical epithelial cells by HPV, a non-specific 
response is provoked, accompanied by an inflammatory process, neutrophil 
chemoattraction, macrophage activation, natural killer (NK) cell intervention, production of 
natural antibodies, and activation of the complement system, which forms the first non-
specific yet defensive immunological barrier. Prolongation of the response over time and 
protection against future infections requires specific immunological mechanisms (Alba et al., 
2009; Kadish et al., 1992; Rodríguez-Cerdeira et al., 2009c). T CD4 lymphocyte activation 
requires recognition of the surface molecules exposed by the presenter cell. The viral 
peptide along with class II HLA will be recognised in the context of T cell receptor and CD4, 
but requires a ‘safety’ mechanism for deactivation process control. Thus, it is necessary that 
other molecules such as CD40 and B7 that are present on the presenter cell surface be 
recognised by their receptors (CD40 linking and CD28, respectively) for activation to occur. 
Each activated T CD4 lymphocyte will be converted into a type 1 or 2 lymphocyte T helper 
cell depending on a series of local tissue factors fundamentally comprising antigen entry 
route, processing mechanism, and the presence of different interleukins. The Th1 pathway 
will induce T CD8+ lymphocyte maturity towards cytotoxic effector cells (Fig. 5) (Alba et al., 
2009; Rodríguez-Cerdeira et al., 2009c, 2009d). 
 
Fig. 5. Lymphocyte activation towards cytotoxic effector cells 
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Specific cells existing in the cervical epithelium are capable of acting as antigen presenters. 
Although some keratinocytes develop this ability, Langerhans reticular cells are the true 
antigen presentation specialists in the cervical epithelium. These cells absorb the viral 
particles to digest them into endosomes and start an activation process that includes 
presentation on the antigen surface together with the presenter cell HLA. These activated 
cells will be recognised by the T CD4 lymphocytes in the case that they recognise every 
molecule in the correct environment, after which, they evolve into lymphocyte helpers (Th) 
in the local context of the expression of certain interleukins (IL). Depending on IL type, it 
will advance to differentiation towards a Th1 pathway that will induce the activation and 
proliferation of T CD8+ cytotoxins with specific immunity (CTL+8) or towards a Th2 
pathway that will induce the activation and expansion of B lymphocytes, which differentiate 
towards plasma-antibody producer cells for the viral base proteins of non-specific immunity 
that we could identify as prophylactic (Alba et al., 2009). CTL+8 would have the ability to 
act against the established viral infection, while the plasma B cells produce antibodies act 
against the external viral antigens that are exposed during this and successive HPV 
infections. 
The nature of antibody responses and duration following HPV vaccination plays a key role 
in long-term protection against HPV infection. The importance of vigorous and prolonged 
immune protection is also very important. In addition, it provides maximum benefit against 
cervical cancer and other HPV-related cancers (Alba et al., 2009; Rodríguez-Cerdeira et al., 
2008a, 2009c, 2009d ). Nevertheless, it should also be highlighted that long-term protection is 
not fully predictable at the introduction of any vaccine, because it varies according to many 
variables (e.g. cohort target, coverage, acceptance, catch-up) that are not strictly related to 
immune response. Although some researchers have developed a model to predict long-term 
immunity, it remains an ongoing and challenging issue. HPV is a family of many different 
genotypes. Ideally, a vaccine should cover at least the majority of the genotypes that are 
linked to tumour development, i.e. those that are considered HR-HPV. Nevertheless, the 
large number of different genotypes among the HPV viruses raises the question about the 
number of HPV viruses that must be included in the vaccine preparation process. Thus, the 
possibility of developing second-generation cross-reacting vaccines covering a larger 
portion of the HPV family must be considered in the HPV investigation (Mariani  & Venuti , 
2010) biological evolution is concerned, HPV strains are successful infectious agents. They 
induce persistent infections without causing frequent or serious complications for the host 
and shed virions for transmission to other naive individuals. To achieve this lifestyle and 
maintain a state of equilibrium, HPV must avoid the host's defence system. Many factors 
contribute to evading immune pools, particularly, the following:  
• Virus capsid entry is usually an activating signal for dendritic cells (DCs). 
• Free virus particles are shed from the surface of the squamous epithelia with poor 
access to the vascular and lymphatic channels and to the lymph nodes where immune 
responses are initiated. 
• Most DNA viruses have mechanisms for inhibiting interferon (IFN) synthesis and 
receptor signalling, and papillomaviruses are no exception. 
Despite HPV's ability to evade the host’s immune system and to down-regulate innate 
immunity, a primary HPV infection is cleared naturally in approximately 90% of the cases, 
thus indicating the central role of immunity in the resolution of cervical and anogenital 
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HPV-associated diseases. Innate immunity acts as the first line of non-specific defence 
against any pathogen (DCs, IFN-ǂ, cytokines, neutrophils, and macrophages), and attacks 
by HPV should be detected by the intraepithelial DCs. There is evidence indicating that DCs 
are not activated by the uptake of HPV capsids, suggesting a limited role in the host’s 
response to HPV infection (Mariani  & Venuti , 2010; Fausch et al, 2002, 2003). 
Other critical point is in regards to the long-term clinical significance of immunity evoked 
by natural infection. Certain studies have showed that some women in the placebo group 
developed the disease despite consuming antibodies against the offending HPV types at 
enrolment, thus confirming, as stated in the recent WHO position paper, that host 
antibodies directed against the viral L1 protein do not necessarily protect against 
subsequent infection by the same HPV genotype (Fausch et al, 2002; Olsson et al., 2009; 
World Health Organization [WHO], 2009).  
3. Prophylactic vaccines against human papillomavirus 
Prophylactic vaccines against HPV infection, which are currently in the advanced stage of 
development and evaluation, seem to give more hope than the therapeutic ones, whose 
objective is to prevent new infections. Various approaches have been examined, namely, 
recombinant live vector vaccines, protein and peptide vaccines, vaccines without DNA, and 
innocuous vaccines. The most advanced vaccines against HPV consist of particles that are 
similar to the virus called virus-like particles (VLP). These substances are created by L1 and 
L2 proteins. These particles do not contain DNA and are synthesised through self-assembly 
of the proteins of the upper antigen of the L1 capsid. VLPs, constructed by genetic 
engineering, are structures that are identical to the native virus but do not have an infectious 
capacity. The lower structural protein L2 can assemble with L1 and form an even more 
stable VLP. Their antigenic similarities with the genuine HPV virions explain why VLPs 
introduce a powerful humoral response with neutralising antibodies (Rodríguez-Cerdeira et 
al., 2009c, 2009d). 
3.1 Do those vaccines activate the immune memory system?  
The WHO explicitly stated that the induction of immune memory should be assessed by 
means of evaluating immune responses to additional doses of vaccine administered at 
planned intervals following the completion of the primary series. Subsequently, the 
immune-memory anamnestic response using an antigen challenge has been reported for the 
quadrivalent vaccine. Nevertheless, the questions in vaccinated women include the 
following: Does natural re-exposure to the same HPV type vaccine significantly boost 
antibody levels, which contributes to the long-term persistence of anti-HPV responses, and 
consequently, does it improve protection over the next few decades? Time is needed to 
suitably answer this question (WHO, 2006; Olsson et al., 2007)  
Einstein et al. while comparing the immune response and reactogenicity of 2 vaccines by 
using the same pseudovirion-based neutralisation assay, stated that for any age strata, the 
positivity rates for the anti-HPV 16 and 18 neutralising antibodies in the cervicovaginal 
secretions and circulating HPV 16- and 18-specific memory B cell frequencies were higher 
after vaccination with the bivalent vaccine compared to the quadrivalent vaccine (Einstein et 
al., 2009). Regan et al. (24) considered transient infection in estimating the impact of an HPV 
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16 vaccine in Australia and showed that it has significant implications on patient immunity 
and overall vaccine effectiveness (Regan et al., 2007).  
In our experience, the vaccines induced very high concentrations of neutralising antibodies, 
much higher than those for natural infection, and the seroconversion rates in the trials 
approached 100%. In a recent study, we evaluated whether women with naturally acquired 
HPV antibodies who were HPV DNA-negative at the baseline were less likely to develop 
new infection with the same HPV type than the HPV antibody-negative and DNA-negative 
women were. HPV infection rates were assessed over a year. New infections were detected 
by type-specific PCR according to the baseline HPV 6/11/16/18 serostatus. Our findings 
suggest that natural immunity does not reliably protect against new infections with HR-
HPV types. Only a small proportion of women with naturally acquired antibodies had 
limited protection against incidental and persistent infection with 1 HPV type. Therefore, 
our results support vaccination of all women regardless of the naturally acquired-HPV 
antibody status (Rodríguez-Cerdeira C et al., 2009b). The medium-term objective of these 
vaccines is the prevention of precursory lesions of cervical cancer and cervical intraepithelial 
neoplasia (CIN), especially CIN 3. Furthermore, many studies have been published in 
favour of protection against vulvar and vaginal neoplasias by using the tetravalent vaccine 
(WHO, 2006). The final long-term objective of prophylactic vaccines for HPV is the 
prevention of invasive cervical carcinoma. Associated objectives include the prevention of 
other forms of HPV-related cancer, namely, those that target the vulva, vagina, anus, penis, 
and oropharynx (Olsson et al., 2007). 
Some researchers are much more sceptical about the effectiveness of trying to establish 
vaccines and new models of transmission of HPV infection. They postulate that the future 
aim of globally eradicating HPV-associated pathologies will be achieved by the local 
production of antigens with cross-reactivity among the different HPV types. In addition, 
they state that while sensitive methods are available for the detection of viral genetic 
material (DNA and RNA), we do not have a definitive method for determining the 
infectious state of an individual, from the perspective of transmission of infections. 
Furthermore, currently, as we do not have any reliable correlates of immune protection 
against infection, we are unable to precisely report whether an individual has acquired 
immunity to infection, either through exposure to infection or vaccination; what level of 
protection has been conferred or how long it will last; or whether this protection will 
prevent further transmission (Olsson et al., 2007). 
Clinical trials have shown that quadrivalent vaccine effective against anogenital warts but 
they have not ruled out the possibility that transient infection may lead to transmission. We 
have discussed several areas of uncertainty that are less important. The extent to which 
condoms and circumcision are protective against infections has not been firmly established. 
To date, modellers have assumed that transmission occurs via heterosexual penile-vaginal 
intercourse, because the greatest disease burden is cervical cancer and this mode of 
transmission is both the most studied and the best understood. However, other modes of 
transmission must be considered more closely if their role in other diseases such as anal and 
oropharyngeal cancers is to be studied. Unfortunately, for modellers, most studies of HPV 
natural history have not been designed to improve  models but rather to answer broader 
questions. Studies of transmission in couples have not been carried out on a large enough 
scale or with sufficient sampling to clearly observe and measure transmission. It is our hope 
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that as the demand for accurate quantitative modelling studies to evaluate the impact of 
vaccination programs increases, studies will increasingly be designed with model 
parameterisation in mind (WHO, 2006; Olsson et al., 2007; Regan et al., 2007). Other research 
regarding prevention indicates that oncogenic virus-mediated cell fusion induces 
chromosomal instability and tumours (Gao  & Zheng , 2011). 
An expanding body of work including tissue culture studies, mouse models, and human 
patients suggests that tetraploidy is a precursor of the chromosomal instability state and the 
diploid-tetraploid-aneuploid sequence. It has also been reported that tetraploid cells tend to 
activate a p53 response that leads to G1 arrest and ultimately senescence or apoptosis. Thus, 
deregulation of the cell cycle checkpoint and apoptosis will provide tetraploid cells an 
opportunity to undergo dysplasia and become oncogenic aneuploid cells, which has been 
verified by both in vivo and in vitro experiments. It is remarkable that all human oncogenic 
viruses can express proteins that have the ability to inhibit pRb and p53, two critical 
regulators of both the cell cycle and apoptosis (Storchova & Kuffer , 2008; Castedo et al., 
2006). 
Therefore, multicellular organisms need to be equipped with tools that allow them to detect 
and remove those cells. Multiple lines of evidence suggest that p53-dependent apoptosis is 
the major tool for eliminating accidental tetraploid cells, which cannot undergo normal 
mitosis and will trigger cell cycle checkpoints. Both p53 and pRb may function as tumour 
suppressors in this context. Nonetheless, tetraploid cells produced by oncogenic virus-
mediated cell fusion can sometimes overcome this arrest and continuously proliferate as 
human oncogenic viruses, expressing oncoproteins and having the ability to perturb pRb, 
p53, and/or apoptotic proteins. For example, HR-HPV E6 and E7 can inhibit the functions of 
p53 and pRb, respectively (Castedo et al., 2006; Narisawa-Saito & Kiyono, 2007). Once the 
tetraploid cells resulting from oncogenic virus-mediated cell fusion survive and proliferate, 
they may undergo dysplasia, a hallmark of most malignant tumours (Holland & Cleveland, 
2009).  
Chromosome stability is related to mitosis. The oncoprotein HPV-16 E5 was recently 
determined to have fusogenic activity and to lead to increased incidence of CIN, particularly 
in the presence of p53 and pRb inhibitors HPV 16 E6 and E7, respectively. Moreover, it 
should be noted that HPV-16 E5 must be expressed on both cells for cell fusion to occur. In 
this model, 2 cervical cells both expressing E5 fuse at a high rate and the resulting tetraploid 
cell undergoes CIN with the help of E6 and E7 to ultimately become an aneuploid cervical 
cancer cell. Of course, accumulation of deleterious mutations in the fused cells may also lead 
to the extinction of pre-malignant lesions before they become cancerous (Hu  & Ceresa, 
2009). 
However, this model is challenged by 2 facts. First, either HR-HPV E6 or E7 alone can also 
contribute to tetraploid cell formation by inducing cytokinesis failure (Incassati et al., 2006; 
Heilman et al., 2009; Duensing et al., 2001a). Second, it is widely accepted that increasingly 
deregulated expression of E6 and E7 has been identified as the major transforming factor in 
the pathogenesis of cervical dysplasia and derived cancers.  
However, our model and these 2 facts are not mutually exclusive. First, in vitro and clinic 
studies have revealed that CIN and aneuploidisation seem to precede and favour HPV 
genome integration, prior to which the expression of E6 and E7 is low for tight restriction in 
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host cells. Second, E5 is thought to play a role only in the early stage because E5 expression 
is inhibited by HPV genome integration, but E6 and E7 act throughout carcinogenesis, 
especially after integration. This model is also supported by a study showing that the 
formation of tetraploid cells is primarily attributed to E5 and E5-induced cell fusion rather 
than E6/E7 and cytokinesis failure. Therefore, cytokinesis failure induced by E6 or E7 in an 
over-expression system may only occur in the late stage, whereas E5-mediated cell fusion 
may play a key role in initial cell transformation (Duensing et al., 2001a, 2001b; Melsheimer 
et al., 2004). 
According to the mechanisms discussed above, cell fusion is also a potential and necessary 
mechanism for cancer progression since tumour cells would degenerate and become extinct 
for fusion among cancer cells with distinct potency and may also accelerate cancer 
evolution. This conjecture has been confirmed in a study that showed that in vitro or in vivo 
spontaneous fusion between the bone- and lung-tropic sub lines of human breast cancer cell 
line MDA-MB-231 can produce hybrids with dual metastasis organotropism. Cell fusion 
with metastatic cancer cells can also endow primary cancer cells the ability to resist the 
cytolytic activity of cytotoxic T lymphocytes. Given these considerations, the development 
of fusion inhibitors would be beneficial for cancer prevention and treatment of virus-
associated cancers, since they would inhibit the entry and spread of the virus and affect the 
oncogenic role (Lu & Kang, 2009; Lee et al., 2000).   
4. Therapeutic vaccines 
The investigation of therapeutic vaccines capable of providing specific cell-mediated 
immunity is justified. The possible indications for the therapeutic vaccine include: (1) post-
exposure, (2) diagnosis of low-grade squamous intraepithelial lesion (L-SIL), and (3) 
diagnosis of high-grade squamous intraepithelial lesion (H-SIL) or invasive cancer (15,-17). 
Data from dog and rabbit models hint that vaccines with E1 and E2 genes as targets would 
be suitable for both post-exposed and L-SIL women. Nonetheless, in women affected by 
CIN 2/3 or cancer, continuous expression of E6 and E7 oncogenes is essential for 
progression and maintenance of the malignant phenotype. The experimental E6 and E7 
vaccines have shown immunogenicity and effectiveness in transplantable tumour models in 
rodents. Nevertheless, human trials have demonstrated immunogenicity and safety but very 
limited effectiveness (Rodríguez-Cerdeira et al., 2009d; Fausch et al, 2002). 
Therapeutic vaccines should be able to induce specific immunity mediated by the cells 
capable of preventing lesion development or eliminating existing lesions or even malignant 
tumours by using recombinant peptides derived from E6 and E7 oncogenes (minigenes) 
(Rodríguez-Cerdeira et al., 2009d). Various vaccine approaches based on the E7 protein or 
peptides representing the T cell epitopes have been developed and tested in preventive and 
therapeutic pre-clinical tumour models. Although effective in preventing the growth of 
transplantable E7-expressing tumours in mice, these vaccines have demonstrated only 
moderate efficacy in therapeutic settings. Although the exact mechanism of the vaccine 
failure is yet to be defined and is probably complex, the active immune evasion mechanisms 
employed by the tumour may play a critical role. The success of E7 TAA-based therapeutic 
vaccines against cervical cancer, therefore, may require vaccine formulations containing 
adjuvants that not only generate E7-specific potent immune responses but also overcome 
the tumour-mediated immune evasion mechanisms.  
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Co-stimulation plays a critical role for the generation of adaptive immune responses. We 
recently proposed that vaccine formulations containing co-stimulatory ligands may have 
efficacy in therapeutic cancer settings. We particularly focussed on the 4-1BBL, a co-
stimulatory member of the tumour necrosis factor (TNF) family, because of the critical role 
played by 4-1BB signalling in the generation and maintenance of CD8+ T cell memory, 
which is critical for tumour eradication (Uno et al., 2006). Although 4-1BBL has no function 
as a soluble trimeric molecule, we generated a chimeric recombinant SA-4-1BBL in which 
the extracellular portion of this molecule was cloned at the C-terminus to the core 
streptavidin (SA). This chimeric molecule exists as tetramers and oligomers and has potent 
co-stimulatory activity on the CD4+ and CD8+ T cells in the soluble form. Vaccination with 
SA-4-1BBL and E7 peptide representing the dominant CD8+ T cell epitope resulted in 
effective eradication of the E7-expressing TC-1 tumours. The therapeutic efficacy of the 
vaccine was superior to other vaccine formulations containing an agonistic antibody (Ab) to 
the 4-1BB receptor or toll-like receptor agonists such as lipopolysaccharide, 
monophosphoryl lipid A, and CpG (Rabu et al., 2001; Elpek et al., 2007; Schabowsky et al., 
2009).  
Sharma et al. tested the efficacy of SA-4-1BBL as the immunomodulatory component of an 
E7 protein-based vaccine in the TC-1 tumour model as a prelude to phase I cancer. Use of 
whole E7 protein as the antigenic component of the vaccine alleviates the concerns related to 
the use of a single peptide representing a CD8+ T cell dominant epitope that includes the 
following: (i) saturation of immune response due to antigen exhaustion; (ii) lack of CD4+ T 
cell help, which can limit the vaccine’s anti-tumour efficacy; (iii) lesser magnitude and 
duration of the immune response towards a single epitope compared to the collective 
responses to multiple epitopes; (iv) higher possibility of immune-edited escape variants; and 
(v) requirement for HLA compatibility that will limit the target patient populations ( 
Sharma et al., 2010). .  
We herein showed that single vaccination with SA-4-1BBL and a recombinant whole E7 
protein resulted in the eradication of the established tumours in 70% of the test mice. The 
therapeutic efficacy of the vaccine was associated with robust primary and memory T cell 
responses, Th1 cytokines, enhanced intra-tumoural CD4+ and CD8+ T cell infiltration, and 
NK cell function. Taken together, these data corroborate the utility of SA-4-1BBL as a novel 
multifunctional immunomodulatory component of therapeutic vaccines and justify testing 
of the E7 protein-based vaccine formulation in human clinical trials. Sharma et al.  in there 
studies concluded that the therapeutic efficacy of whole E7 protein and SA-4-1BBL vaccines 
in the TC-1 tumour model was comparable to the efficacy obtained using a synthetic peptide 
representing the dominant CD8+ T cell epitope for E7 protein as the antigenic component of 
the vaccine. The comparable therapeutic efficacies of the peptide and whole E7 protein-
based vaccines may be due to both the vaccine formulation and the tumour model used in 
these studies. Both the vaccine formulations included equal amounts of antigen and 
therefore, more molar amounts of the peptide. The excess peptide amount and its faster 
kinetics of presentation by MHC class I molecules may allow robust generation of a CD8+ T 
cell response that curbs tumour growth ( Sharma et al., 2010, Yan et al., 2009).  
As much as the TC-1 tumour model uses transplantable tumours and has fast growth 
kinetics, antigen escape variants due to immunological pressure may not occur during the 
experiment. However, this may be different in a spontaneous tumour setting wherein 
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immunological pressure may possibly give rise to antigen-loss variants. Therefore, use of 
either whole E7 protein-based vaccine or those with both and E7 proteins may have better 
efficacy in a spontaneous setting due to the availability of not only multiple CD8+ but also 
CD4+ T cell epitopes (44). Consistent with this notion, we demonstrated potent primary and 
memory CD4+ and CD8+ T cell responses in mice vaccinated with E7 protein and SA-4-
1BBL. Although CD4+ T cells seem unnecessary for primary immune responses, it is critical 
for the generation and maintenance of long-term memory and recall responses (Gunn et al., 
2001; Kumaraguru et al., 2005).  
The development of non-toxic adjuvants that not only activate the effector arm of the 
immune system against tumours but also overcome various immune evasion mechanisms 
employed by the vaccines against cancer is important. Importantly, we previously reported 
the pleiotropic effects of SA-4-1BBL on the cells of innate, adaptive, and regulatory 
immunity (Alba et al., 2009), and treatment with SA-4-1BBL at therapeutic doses did not 
result in detectable signs of acute toxicity that were recently reported for agonistic 
antibodies to 4-1BB and were assessed by lymphadenopathy, lymphocyte proliferation, 
systemic cytokine response, and gross pathology (Fausch et al, 2002, 2003). Taken together, 
our findings support the notion that SA-4-1BBL is a potentially effective and safe adjuvant 
that can serve as a component of therapeutic vaccines. Testing its therapeutic efficacy in 
clinical trials will be important; if effective, this molecule may serve as a safe and effective 
platform for the development of therapeutic vaccines against cancer and chronic infections 
(Sharma et al., 2010).  
In order to evaluate the therapeutic potential of the responses of L1-specific CD4+ and CD8+ 
T lymphocytes in cervical cancer patients, L1 VLP-loaded DCs were used to stimulate 
peripheral blood lymphocytes from the cervical cancer patients, and such responses were 
compared to those elicited by the E7 oncoprotein. We showed by reverse transcriptase (RT)-
PCR that all the flash-frozen cervical biopsy samples collected from HPV 16-positive 
cervical cancer patients harboured L1 in addition to E6 and E7 RNA. The E7 RNA copy 
number (mean, 176.2) was significantly higher than those of E6 RNA (mean, 47.3) and L1 
(mean, 58.3) in HPV 16-positive cervical cancers (P < 0.0001 and P < 0.001, respectively). 
However, no significant differences between the levels of expression of E6 and L1 were 
noted. Kinetic studies of E6, E7, and L1 RNA and protein expression levels in primary 
tumours showed sharp reductions in L1 expression versus E6 and E7 expression after 
multiple in vitro passages. Autologous DCs pulsed with HPV 16 VLPs or recombinant full-
length E7 elicited strong type 1 L1- and E7-specific responses in CD4+ and CD8+ T cells 
from cervical cancer patients. Importantly, L1 VLP-specific CD8+ T lymphocytes expressed 
strong cytolytic activity against autologous tumour cells and were as effective as E7-specific 
cytotoxic T lymphocytes in lysing autologous tumour cells naturally infected by HPV 16. 
Taken together, these data demonstrate consistent expression of L1 in primary cervical 
tumours and the possibility of inducing effective L1/tumour-specific CD4+ and CD8+ T-
lymphocyte responses in patients harbouring HPV-infected cervical cancer. These results 
may have important implications for the treatment of patients harbouring established HPV-
infected lesions with L1 VLPs or combined E7/L1 DC-based vaccinations (Shedlock & Shen, 
2003; Bellone et al, 2009).  
One novel cancer therapy involves using the vascular disrupting agent 5,6-
dimethylxanthenone-4-acetic acid (DMXAA). In the current study, we aimed to test the 
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combination of DMXAA treatment and HPV-16 E7 DNA vaccination to enhance the anti-
tumour effects and E7-specific CD8+ T cell immune responses in treated mice. We 
determined that DMXAA treatment generates significant therapeutic effects against TC-1 
tumours but does not enhance antigen-specific immune responses in tumour-bearing mice. 
We then found that the combination of DMXAA treatment and E7 DNA vaccination 
generates potent anti-tumour effects and E7-specific CD8+ T cell immune responses in the 
splenocytes of the tumour-bearing mice. Furthermore, the DMXAA-mediated enhancement 
or suppression of E7-specific CD8+ T cell immune responses generated by CRT/E7 DNA 
vaccination depended on the time of DMXAA administration and was also applicable to 
other antigen-specific vaccines. DMXAA is a synthetic flavonoid that induces the production 
of local cytokines, including TNF-ǂ. DMXAA has been shown to induce anti-tumour effects 
in animal models, especially in combination with established anti-cancer agents. It has also 
demonstrated a good safety profile and looks promising after phase I clinical trials (Peng et 
al., 2001 Shedlock & Shen, 2003; Silk & Finn, 2007). 
Mice were immunised with 2 μg of various DNA vaccines and received boosters with the 
same regimen as indicated in the figure legends. For vaccinia encoding SigE7LAMP1 
vaccination, 1 × 107 plaque-forming units (pfu) viruses were intraperitoneally injected in a 
volume of 100 μL. Splenocytes were harvested 1 week after the last vaccination. DMXAA 
treatment generates significant therapeutic effects against TC-1 tumours but does not 
enhance antigen-specific immune responses in tumour-bearing mice. To determine the anti-
tumour effects of DMXAA treatment, we first challenged groups of C57BL/6 mice (5 per 
group) with TC-1 tumour cells and treated them with a single dose of DMXAA that was 
administered on day 13 after tumour challenge via intraperitoneal injection, and monitored 
the tumour size over time. Tumour-bearing mice treated with DMXAA showed significantly 
lower tumour volumes over time compared to tumour-bearing mice not treated with 
DMXAA. We also characterised the E7-specific CD8+ T cell immune responses in these 
mice. One week after DMXAA treatment, the splenocytes from tumour-bearing mice were 
harvested and characterised for E7-specific CD8+ T cells by using intracellular IFN-Ǆ 
staining followed by flow cytometry analysis.  
Combination of DMXAA treatment with E7 DNA vaccination generates potent anti-tumour 
effects and E7-specific CD8+ T cell immune responses in the splenocytes of tumour-bearing 
mice. In order to determine the therapeutic anti-tumour effects and E7-specific CD8+ T cell 
immune responses in TC-1 tumour-bearing mice treated with DMXAA and CRT/E7 DNA 
vaccination, we first challenged groups of C57BL/6 mice (5 per group) with TC-1 tumour 
cells and then treated them with CRT/E7 DNA vaccine with or without DMXAA. Seven 
days after the last vaccination, we harvested the splenocytes from the vaccinated mice and 
characterised them for the presence of E7-specific CD8+ T cells by using intracellular 
cytokine staining for IFN-Ǆ followed by flow cytometry analysis. The tumour-bearing mice 
that were treated with CRT/E7 DNA vaccine in combination with DMXAA experienced 
better therapeutic anti-tumour effects than the mice treated with any other regimens. 
Furthermore, mice treated with the DNA vaccine in combination with DMXAA also 
generated the highest number of E7-specific CD8+ T cells compared to the mice treated with 
any of the other regimens.  
In summary, the authors tried to show that the combination of DMXAA treatment and 
HPV-16 E7 DNA vaccination can enhance or suppress the anti-tumour effects and E7-
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specific CD8+ T cell immune responses in treated mice depending on the time of DMXAA 
administration. These results may have potential implications for future clinical translation. 
Therefore, further work needs to be done to complete this study (Bellone et al, 2009; Peng et 
al., 2001; Shedlock & Shen, 2003; Silk & Finn, 2007). 
5. Vaccines, prophylactics, and therapeutics  
In the study by Petrone et al. (Petrone et al, 2011) that aimed to obtain a highly 
immunogenic E7 preparation, they did not focus on obtaining identical particles since 
particles of different sizes can be taken up by different types of antigen-presenting cells such 
as the DCs, macrophages, and polymorphonuclear leukocytes, sustaining a more potent 
immune response (Uno et al., 2006; Rabu et al., 2001). However, we standardised the 
different preparations by using semi-quantitative counting of the particles on EM 
micrographs (not shown). The immunogenicity of Escherichia coli-derived E7 fused through 
the N-terminus to either HPV16 E6 or GST was also investigated in mice. An antigen-
specific immune response of Th2 polarity was obtained when the fusion proteins were 
administered to the mice without an adjuvant (data not shown). However, we were unable 
to observe the typical micro- and nanoparticles in these E7-fusion proteins prepared from E. 
Coli. Recently, the cytosolic accumulation of E7 oligomers shown in HPV 16 cervical cancer 
cell lines and in clinical samples by indirect methods supports a new hypothesis regarding 
the presence of E7 isoforms and their role in different cell compartments (Dantur et al., 2009; 
Knapp, et al. 2009). The presence of E7 in different aggregation forms and cell compartments 
could affect E7 processing and presentation by MHC I and II molecules, assessing both the 
strength as well as the quality of the host’s anti-HPV immunity. More studies on 
recombinant E. coli-derived E7 assembled in different forms would contribute to explaining 
the stimulation of the different branches of the immune system in the HPV16 mouse tumour 
model (Knapp et al., 2009). 
Significant differences exist between the HPV 16 mouse tumour model and human HPV 16-
dependent diseases. However, studies on the immunoglobulin G (IgG) subclasses and their 
FcgR receptors between mice and humans are comparable. HPV 16 E7 immunogenicity 
studies in mouse will provide insights into the understanding of the protective immunity 
against human HPV 16 infections as well. 
Commercial preventive HPV vaccines have high production costs, which has prevented 
the implementation of widespread vaccination programs. Recently combined preventive 
and therapeutic HPV vaccines produced in E. coli have been described (Knapp, et al. 2009; 
Schädlich et al., 2009; Bian et al., 2008), and the data presented here suggest a possible use 
of E. coli-derived E7 in the particle form in subunit vaccines. The E. coli-expressed proteins 
represent a well-studied and cost-effective means for vaccine production. These methods 
require reduced time, cost, and labour, and can be easily scaled up to industrial-scale 
production. Generation of new low-cost HPV vaccines could represent the only possibility 
for women living in developing countries to gain access to HPV vaccination programs in 
order to prevent or treat pre-cancerous lesions and cancer (Rubio I et al., 2009). In this 
paper, the author describes, for the first time, the use of recombinant HPV 16 E7 
assembled in vitro into particulate form to induce protective immunity against an HPV 16-
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related tumour in an HPV-16 mouse tumour model. Data show that E7 particles used 
without adjuvant are excellent stimulators of the immune system. In C57BL/6 mice, the 
E7 preparation induces anti-tumour immunity sustained by both humoral and cell-
mediated immune responses. This E7 protein (derived from E. coli) that does not require 
an adjuvant could represent, along with the recently proposed E. coli-derived HPV 
antigens ((Knapp, et al. 2009; Yan et al., 2009), a low-cost constituent for the development 
of a new generation of HPV 16 vaccines that combines prophylactic and therapeutic 
activities.  
Numerous methods have been developed to introduce foreign genes into mammalian cells, 
including chemical-based procedures, electroporation, gene gun, and mammalian viral 
vector-based systems. These methods have the following advantages: ease of use, gene 
capacity, cell specificity, cytotoxicity, efficiency, safety, and reproducibility. High cost of 
these methods can be the only limitation. To overcome this problem, recombinant 
baculoviruses have been widely developed using baculovirus/mammalian expression 
systems. These recombinant baculoviruses will be used extensively for gene therapy and 
vaccines, nevertheless, the authors did not observe substantial spot numbers in any of the 
mice treated with wild-type baculovirus. However, when we performed immunostaining 
for the splenocytes harvested from the mice intramuscularly injected with wild-type 
baculovirus, we observed non-specific IFN-Ǆ production in 2 of the 6 mice. Several recent 
studies indicated that baculoviruses may induce innate immune responses (Strauss et al, 
2007;  Li et al., 2009; Abe et al, 2003, 2005; Huang et al.,2009). Although baculoviruses do not 
replicate in mammalian cells and thus can serve as safe DNA vaccine vectors, additional 
information is required on the pre-existing anti-vector immunity from the use of live 
baculoviruses for vaccine development. 
In another study (Liao et al., 2008), a recombinant pseudotype baculovirus (BV-G-E) was 
generated by inserting the JEV E gene fragment into the pFastBac-VSV/G vector. The 
authors demonstrated that BV-G-E could elicit high protective immunity in mice. The 
amounts of BV-G-E injected into mice were 1 × 108, 1 × 109, and 1 × 1010 pfu. In yet another 
study, without the use of recombinant baculovirus, mice were inoculated intramuscularly 
with a single dose of 5 × 106 pfu of recombinant attenuated vesicular stomatitis virus 
(rVSV) expressing HPV16E7 protein. The authors suggested that rVSV-based vaccination 
should be explored as a therapeutic strategy for cervical carcinoma. Other recherche 
group (Lee et al., 2010) developed a novel DNA vaccine for HPV; a recombinant 
baculovirus-bearing human endogenous retrovirus (HERV) envelope protein, which 
cannot replicate in mammals, was used as a nano-carrier for the HPV-16L1 DNA vaccine 
(AcHERV-HP16L1). For the in vivo test, mice were injected intramuscularly with 107 
particles of the constructs, with 2 boosters given at 2-week intervals. Compared to 
Gardasil® (25 μl/dose), the AcHERV-HP16L1-immunised mice showed similar high levels 
of humoral immunity in IgG/IgA and in HPV pseudovirion neutralisation. Combined 
immunisation (AcHERV-HP16L1 primer and Gardasil® booster) induced slightly higher 
neutralising activity. Compared to the group treated with Gardasil®, the mice immunised 
with AcHERV-HP16L1 showed 450- and 490-fold increases in IFN-Ǆ at 5 and 20 weeks 
after the first priming, respectively. The safety levels were comparable. The combined 
immunisation conferred lower T cell immunity than AcHERV-HP16L1 treatment. The 
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advantages of our novel AcHERVHP16L1 vaccine over Gardasil® include higher cellular 
immunogenicity and considerably lower production costs.  
The recombinant baculovirus used for HPV16L1 gene delivery does not replicate in the 
host. Its advantages include safety, ease of processing, and most importantly, the ability 
to induce both humoral and cellular immunity. Therefore, we suggest that the AcHERV-
HPV DNA vaccine be developed as an efficient prophylactic and therapeutic vaccine. On 
the basis of its advantages, we anticipate that the developed AcHERV- HP16L1 will 
contribute to global HPV prevention (Chen et al., 2000; Velders et al, 2001; Mahdavi & 
Monk, 2005). 
Acceptance of the vaccine among adolescents and parents, protection against sexually 
transmitted infections (STIs), and adequate health support and recommendation are the 
keys to the success of HPV vaccines. Recent studies have shown that although some parents 
find the vaccine acceptable, others believed that their children are not at real risk of 
contracting an STI or expressed concern that vaccination may encourage the practice of risky 
sexual behaviours. In a recent survey, mothers of children aged between 8 and 14 years 
expressed a willingness to vaccinate their daughters (67%) or children (66%). Those who 
refused the vaccine cited the risk of unknown side effects, lack of sexual activity at the time, 
and the lack of a direct benefit in male children. In another parent survey, vaccination rates 
of 10–15-year-old children increased from 55% to 75% after the parents read a newsletter. 
Therefore, it is essential that accurate information about the disease and the vaccine be 
distributed by health professionals to ensure broad participation in the vaccination 
programs (Roberts et al., 2010; Tsakiroglou et al., 2011; Tan et al., 2010). 
6. Future directions 
In the development of therapeutic HPV vaccines, we have focused on identifying and 
targeting the most relevant antigens associated with cervical cancer, the E6 and E7 HPV 
oncoproteins, which represent tumor-specific antigens and potentially ideal targets for 
therapeutic HPV vaccines. It is important to consider using strategies such as prime-boost 
regimens and/or combinations strategies using molecules that are capable of blocking the 
negative regulators on T cells to further enhance the T cell immune responses. Furthermore, 
increasing understanding of the molecular mechanisms that hinder immune attack in the 
tumor microenvironment will lead to the identification of novel molecular targets that can 
be blocked in order to enhance the therapeutic effect of HPV vaccines. It is conceivable that 
effective therapy against HPV-associated malignancies will probably require a combination 
of therapeutic HPV vaccines with the employment of innovative agents that are capable of 
eliminating the suppressive factors present in the tumor microenvironment. With continued 
endeavor in the development of HPV therapeutic vaccines, it can foresee that HPV 
therapeutic vaccines will become an important approach that can be combined with existing 
forms of therapy such as chemotherapy and radiation therapy to generate better control of 
HPV-associated malignancies (Hung et al., 2008) 
Neutralizing IL10 at the time of PV VLPs immunization increases cytotoxic T cell responses. 
PV VLPs incorporating PV early protein E2, 6 and 7, together with immune stimulator that 
promote strong type 1 responses, and at the same time blocking the effect of IL10 may have 
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therapeutic effect against HPV infection related diseases and are worth further basic and 
clinical investigation (Chen et al., 2011). 
After a long period of scepticism and disbelief, tumour viruses are today recognized as a 
significant cancer risk factor for humans. Much has been learned about the viral 
transforming mechanisms and prophylactic vaccines have been developed against tumour 
viruses’ HPV. Yet, many important issues of tumour virology remain unresolved and 
exciting new ones are emerging from recent discoveries. They define future research 
directions for the field and include (Hoppe-Seyler et al., 2011): 
• Novel strategies for tumour virus hunting. 
• Tumour viruses as experimental tools to study human carcinogenesis.  
• The interplay between viruses and the world of small non coding RNAs.  
• Epigenetic interactions between tumour viruses and the host cell. 
• The role of virus/virus interactions for viral carcinogenesis  
• Novel strategies for prevention and therapy of virus-associated cancers.  
Further study into the tumour microenvironment and molecular mechanisms impeding 
immune attack against HPV will lead to novel targets for therapeutic intervention in the 
future. Discovery of such targets, development of new adjuvants, and improved 
understanding of tumour biology will allow HPV vaccines to be used in combinational 
therapies in a synergistic manner in the future.  
7. Conclusion  
Doubts do remain unresolved, and therefore, the existence of cross-protection evidence in 
the bivalent vaccine against other subtypes of 16/18 capsular structure very similar protein 
suggested that the cause of this cross-immunity would be an extra-immune response 
induced by adjuvant use in the vaccine is unknown. Additional benefit that would represent 
this phenomenon in clinical practice, but how they behave subtypes prevalent highly 
uncertain risk to cause protection from the vaccine subtypes prevalent now? Will it be 
replaced? Because it has been reported that HPV 16/18-positive women are at 5–7-times 
greater risk of acquiring a subsequent infection with HPV 5/7 than the uninfected women, 
can infection be prevented using subtype vaccination?  
We continue with the questions such as whether to vaccinate at-risk populations and what 
type of vaccine to use. We know that the vast majority of HPV infections are diagnosed in 
people at medium risk without appreciable risky behaviours. Protection of these people 
would be very effective because it would disrupt the chain of transmission. One option 
under discussion would be to vaccinate the gay population, which currently has relatively 
high rates of anal cancer linked to HPV and could greatly benefit from the preventive effects 
of the vaccine. Nonetheless, assuming that the vaccine does, in fact, prevent HPV-related 
anogenital and head and neck cancers in males and prevents male-to-female and male-to-
male viral transmission, compelling arguments exist for a gender-neutral approach to 
vaccination. These arguments include the following: (1) female-only vaccination will not 
protect men who have sex with men from contracting HPV and HPV-related diseases and 
(2) the fastest way to achieve the greatest protection for females from cervical cancer and its 
precursors is to vaccinate both females and males. 
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Finally, the economic evaluation of any HPV vaccination strategy requires the measurement 
of clinical benefits and the economic benefits associated with an effective intervention. As 
newer vaccines targeting morbidity rather than mortality are being launched in the market, 
quantification of disease burden and modelling of the cost-effectiveness of intervention 
options are becoming more important when determining the best way to allocate scarce 
health care funds. 
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